Aromatase Inhibitor–Related Symptoms Reported by Postmenopausal Women with Nonmetastatic, Estrogen Receptor–Positive Breast Cancer: A Systematic Review
Research output: Contribution to journal › Review › Research › peer-review
Documents
- Fulltext
Final published version, 1.04 MB, PDF document
Purpose: The objective of this systematic review was to establish an overview of aromatase inhibitor–related symptoms reported by postmenopausal women with nonmetastatic, estrogen receptor–positive breast cancer. Data Sources: Eight databases (PubMed, Cochrane, Cumulative Index to Nursing and Allied Health Literature [CINAHL], Ovid EMBASE, Ovid MEDLINE, PsycINFO, Scopus, and Web of Science) were searched for trials published between January 2004 and November 2021. Inclusion criteria were studies exploring patient-reported aromatase inhibitor–related symptoms in postmenopausal women with nonmetastatic estrogen receptor–positive breast cancer. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Mixed Method Appraisal Tool were used to rate the quality of the trials included. Of 325 full-text papers, 10 were included. Patient-reported symptoms were clustered by using the European Organization for Research and Treatment of Cancer Quality of Life C30 questionnaire domains. Additional domains were used to cluster other symptoms mentioned: menopausal, sex-related, body alteration, and eye-related. The following clusters were the most frequently presented: sex-related (14 symptoms), pain (9 symptoms), insomnia (5 symptoms), and menopausal (5 symptoms). Conclusion: The target group reported a variety of symptoms related to aromatase inhibitors. No tools are currently available to measure all the symptoms reported, indicating a need to revise the tools to acknowledge additional symptoms. Prospective studies are needed to investigate the prevalence of aromatase inhibitor–related symptoms in women with breast cancer. Implication for Nursing Practice: Identification of patient-reported clinically relevant symptoms can enable targeted symptom assessment and management strategies for women with breast cancer undergoing aromatase inhibitor treatment.
Original language | English |
---|---|
Article number | 151487 |
Journal | Seminars in Oncology Nursing |
Volume | 39 |
Issue number | 5 |
Number of pages | 12 |
ISSN | 0749-2081 |
DOIs | |
Publication status | Published - 2023 |
Bibliographical note
Publisher Copyright:
© 2023 The Authors
- Aromatase inhibitors, Breast cancer, EORTC QLQ-C30, Health-related quality of life, Patient-reported symptoms, Symptom management
Research areas
ID: 377804828